PRINCETON, N.J. – November 10, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO) will send CEO Dr. Phillip Chan and CFO Peter Mariani to the Jefferies Global Healthcare Conference in London on November 16-18, 2026, for one-on-one investor meetings.
Investors can book CytoSorbents management meetings through the Jefferies conference website
Meetings can be scheduled through the conference website, or through the company's investor relations team for sessions outside the event. The conference is in its 17th year and is Jefferies' flagship European healthcare investment gathering. It draws C-suite executives, public, private equity and venture capital investors, and strategists across biotech, pharmaceuticals, medical technology, healthcare services, digital health and healthcare IT.
CytoSorb has passed 300,000 cumulative devices in over 70 countries but remains unapproved in the U.S.
CytoSorb, the company's lead blood purification product, is approved in the European Union under CE mark as the first cytokine adsorber. CE mark extensions cover bilirubin and myoglobin removal in liver disease and trauma, and ticagrelor and rivaroxaban removal in cardiothoracic surgery.
In the United States, CytoSorb holds only FDA Emergency Use Authorization for adult critically ill COVID-19 patients with impending or confirmed respiratory failure. It is not approved or cleared there.
DrugSorb-ATR holds two FDA Breakthrough Device Designations but is not yet approved in the U.S. or Canada
The investigational antithrombotic removal system uses polymer technology equivalent to CytoSorb's. It aims to reduce perioperative bleeding in high-risk surgery caused by blood-thinning drugs. One designation covers ticagrelor removal. The other covers removal of the direct oral anticoagulants apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.
CytoSorbents is actively pursuing FDA approval. It will seek Health Canada approval once it has better visibility from the FDA.
CytoSorbents lists its German sales restructuring and 2026 cash-flow break-even target among key risks
The company's forward-looking statements cite the restructuring of its direct sales team and strategy in Germany. They also cite the outcome of FDA and Health Canada submissions, cost reduction and operational optimization, and its ability to finance the business. The company targets cash-flow break-even in the second half of 2026. Further risks are detailed in its Form 10-K filed with the SEC on March 30, 2026.